Processing...
Clinical Trials for Esophageal Cancer
Search
Search
There are 80 active trials for advanced/metastatic esophageal cancer.
Click on a trial to see more information.
80 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with advanced or metastatic solid tumors harboring specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) are eligible for treatment with LY4066434, a highly selective small molecule pan-KRAS inhibitor, given as monotherapy or in combination with standard chemotherapy or immunotherapy regimens. Active CNS metastases and significant unresolved toxicities are exclusion criteria.
ClinicalTrials.gov ID: NCT06607185
HealthScout AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.
ClinicalTrials.gov ID: NCT05902988
HealthScout AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.
ClinicalTrials.gov ID: NCT05544929
HealthScout AI summary: This trial enrolls adults with advanced or metastatic Claudin-1 positive squamous solid tumors (including SqNSCLC, HNSCC, ESCC, or CSCC) who are refractory or intolerant to standard therapies. Patients receive ALE.P02, a CLDN1-targeted antibody-drug conjugate that delivers a tubulin inhibitor selectively to CLDN1-positive tumor cells.
ClinicalTrials.gov ID: NCT06747585
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors expressing Nectin-4 who have progressed after or are ineligible for standard systemic therapy, excluding those with brain metastases or serious comorbidities. Patients receive IPH4502, a novel antibody-drug conjugate targeting Nectin-4 with an exatecan payload, administered as monotherapy.
ClinicalTrials.gov ID: NCT06781983
HealthScout AI summary: This trial enrolls adults with advanced solid tumors—including HNSCC, NSCLC, GI, GU, gynecologic, sarcoma, neuroendocrine, and NUT carcinoma—who have measurable disease and good performance status, to evaluate the intravenous BRD4 degrader MT-4561 administered weekly. MT-4561 is a novel agent targeting BRD4 for ubiquitin-mediated degradation and is being assessed primarily for safety and initial efficacy in this biomarker-unselected population.
ClinicalTrials.gov ID: NCT06943521
HealthScout AI summary: This trial enrolls adults with advanced, FAP-positive solid tumors who have progressed on or lack standard therapy, using [203Pb]Pb-PSV359 SPECT imaging to confirm FAP expression and [212Pb]Pb-PSV359, a FAP-targeted alpha-emitting peptide-radiopharmaceutical, for systemic therapy.
ClinicalTrials.gov ID: NCT06710756
HealthScout AI summary: Adults with previously treated, unresectable advanced/metastatic solid tumors (NSCLC, HNSCC, ESCC, left‑sided CRC) receive ALX2004 monotherapy, an investigational EGFR‑targeted antibody–drug conjugate carrying a topoisomerase I inhibitor payload designed for bystander effect. Excludes candidates for curative local therapy, rapidly progressive disease, short life expectancy, and prior exposure to topoisomerase I inhibitor ADCs.
ClinicalTrials.gov ID: NCT07085091
HealthScout AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.
ClinicalTrials.gov ID: NCT07109726
HealthScout AI summary: Adults with incurable, locally advanced or metastatic solid tumors (e.g., NSCLC, HNSCC, melanoma, TNBC, GI, cervical, CRC, urothelial, clear cell RCC, HCC) receive RO7502175, an afucosylated anti-CCR8 IgG1 designed to deplete intratumoral Tregs via enhanced ADCC, as monotherapy or combined with PD-(L)1 inhibitors (atezolizumab or pembrolizumab). Eligible patients have ECOG 0–1, measurable disease, and no active infections, autoimmune disease, or untreated CNS metastases.
ClinicalTrials.gov ID: NCT05581004